Psa-nadir At 1 Year As A Sound Contemporary Prognostic Factor For Low-dose-rate Iodine-125 Seeds Brachytherapy

dc.creatorReis L.O.
dc.creatorSanches B.C.F.
dc.creatorZani E.L.
dc.creatorCastilho L.N.
dc.creatorMonti C.R.
dc.date2014
dc.date2015-06-25T18:04:24Z
dc.date2015-11-26T15:06:44Z
dc.date2015-06-25T18:04:24Z
dc.date2015-11-26T15:06:44Z
dc.date.accessioned2018-03-28T22:17:09Z
dc.date.available2018-03-28T22:17:09Z
dc.identifier
dc.identifierWorld Journal Of Urology. Springer Verlag, v. 32, n. 3, p. 753 - 759, 2014.
dc.identifier7244983
dc.identifier10.1007/s00345-013-1148-6
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84901306098&partnerID=40&md5=66123bd24cdbc79918913a702bcf93d3
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/88167
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/88167
dc.identifier2-s2.0-84901306098
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1257291
dc.descriptionObjectives: To identify predictors of outcomes in patients with localized prostate cancer treated with iodine-125 brachytherapy in a longitudinal uncontrolled study. Methods: Between 2000 and 2011, 560 histologically confirmed patients were treated with brachytherapy of whom 305 with ≥24-month follow-up and localized tumor were evaluated after exclusion of those locally advanced and under androgen ablation. Results: Patients' mean age was 63.93 years (44-88), mean pretreatment prostate-specific antigen (PSA) was 6.34 ng/mL (0.67-33.09), overall median follow-up was 75.35 months (24-158.37), biochemical recurrence occurred in 17 patients (5.57 %), cancer-specific survival was 100 %, and overall survival was 98.03 %. At multivariate analyses, only PSA-nadir at 1 year and age were related to disease-free survival: To each unit of PSA-nadir, the risk increases 87.3 %-OR 1.87 (p < 0.001; 95 % CI 1.31-2.67), and risk was 4.7 times higher for those under 50 years (vs. >70)-OR 4.69 (p = 0.04; 95 % CI 1.39-18.47). Best cutoff for PSA-nadir at one year was 0.285 (AUC = 0.78; p < 0.001; 95 % CI 0.68-0.89). Kaplan-Meier analysis confirmed PSA-nadir (p < 0.001) as prognostic, while D'Amico's classification failed (p = 0.24). No grade 3 or 4 complication was reported, and only 31.4 % of patients had grade 2 urinary or rectal toxicity. PSA bounce ≥0.4 ng/mL occurred in 18.4 % with no impact on biochemical recurrence. Conclusions: Half (50.49 %) of patients in the scenario of localized prostate cancer treated with iodine-125 brachytherapy reach PSA-nadir at 1 year <0.285, recognized as a key independent prognostic factor. Graphical Abstract: [Receiver Operating Characteristic curve analysis for PSA-nadir at 1 year] [Figure not available: see fulltext.] © 2013 Springer-Verlag Berlin Heidelberg.
dc.description32
dc.description3
dc.description753
dc.description759
dc.descriptionMerrick, G.S., Butler, W.M., Dorsey, A.T., Galbreath, R.W., Blatt, H., Lief, J.H., Rectal function following prostate brachytherapy (2000) Int J Radiat Oncol Biol Phys, 48 (3), pp. 667-674
dc.descriptionSylvester, J.E., Grimm, P.D., Wong, J., Galbreath, R.W., Merrick, G., Blasko, J.C., Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I (125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience (2011) Int J Radiat Oncol Biol Phys, 81 (2), pp. 376-381
dc.descriptionVigneri, P., Herati, A.S., Potters, L., The second decade of prostate brachytherapy: evidence and cost based outcomes (2010) Urol Oncol, 28 (1), pp. 86-90
dc.descriptionRoach III, M., Hanks, G., Thames Jr., H., Schellhammer, P., Shipley, W.U., Sokol, G.H., Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference (2006) Int J Radiat Oncol Biol Phys, 65 (4), pp. 965-974
dc.descriptionRivard, M.J., Butler, W.M., Devlin, P.M., Hayes Jr., J.K., Hearn, R.A., Lief, E.P., Meigooni, A.S., Williamson, J.F., American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103 (2007) Brachytherapy, 6 (1), pp. 34-37
dc.descriptionPotters, L., Morgenstern, C., Calugaru, E., Fearn, P., Jassal, A., Presser, J., 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer (2008) J Urol, 179 (5 SUPPL.), pp. S20-S24
dc.descriptionStock, R.G., Cesaretti, J.A., Stone, N.N., Disease-specific survival following the brachytherapy management of prostate cancer (2006) Int J Radiat Oncol Biol Phys, 64 (3), pp. 810-816
dc.descriptionStock, R.G., Cesaretti, J.A., Unger, P., Stone, N.N., Distant and local recurrence in patients with biochemical failure after prostate brachytherapy (2008) Brachytherapy, 7 (3), pp. 217-222
dc.descriptionKo, E.C., Stone, N.N., Stock, R.G., PSA-nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure (2012) Int J Radiat Oncol Biol Phys, 83 (2), pp. 600-607
dc.descriptionTaira, A.V., Merrick, G.S., Galbreath, R.W., Wallner, K.E., Butler, W.M., Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy (2010) Int J Radiat Oncol Biol Phys, 76 (2), pp. 349-354
dc.descriptionTaira, A.V., Merrick, G.S., Butler, W.M., Galbreath, R.W., Lief, J., Adamovich, E., Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy (2011) Int J Radiat Oncol Biol Phys, 79 (5), pp. 1336-1342
dc.descriptionStone, N.N., Stock, R.G., Unger, P., Intermediate term biochemical-free progression and local control following 125 iodine brachytherapy for prostate cancer (2005) J Urol, 173 (3), pp. 803-807
dc.descriptionZelefsky, M.J., Kuban, D.A., Levy, L.B., Potters, L., Beyer, D.C., Blasko, J.C., Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation (2007) Int J Radiat Oncol Biol Phys, 67 (2), pp. 327-333
dc.descriptionBowes, D., Crook, J.M., Wallace, K., Evans, A., Toi, A., Finelli, A., Jewett, M.A., Catton, C., Results of a surgically derived nomogram to predict Gleason score upgrading applied to a cohort of patients with "favorable-risk" prostate cancer treated with permanent seed brachytherapy (2012) Urology, 80 (3), pp. 649-655
dc.descriptionStokes, S.H., Real, J.D., Adams, P.W., Clements, J.C., Wuertzer, S., Kan, W., Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate (1997) Int J Radiat Oncol Biol Phys, 37 (2), pp. 337-341
dc.descriptionGuarneri, A., Botticella, A., Ragona, R., Filippi, A.R., Munoz, F., Casetta, G., Gontero, P., Ricardi, U., Prostate-specific antigen kinetics after I 125-brachytherapy for prostate adenocarcinoma (2013) World J Urol, 31 (2), pp. 411-415
dc.descriptionStorey, M.R., Landgren, R.C., Cottone, J.L., Stallings, J.W., Logan, C.W., Fraiser, L.P., Transperineal 125 iodine implantation for treatment of clinically localized prostate cancer: 5-year tumor control and morbidity (1999) Int J Radiat Oncol Biol Phys, 43 (3), pp. 565-567
dc.descriptionShapiro, E.Y., Rais-Bahrami, S., Morgenstern, C., Napolitano, B., Richstone, L., Potters, L., Long-term outcomes in younger men following permanent prostate brachytherapy (2009) J Urol., 181 (4), pp. 1665-1671. , Discussion 71
dc.descriptionBurri, R.J., Ho, A.Y., Forsythe, K., Cesaretti, J.A., Stone, N.N., Stock, R.G., Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer (2010) Int J Radiat Oncol Biol Phys, 77 (5), pp. 1315-1321
dc.descriptionMerrick, G.S., Wallner, K.E., Galbreath, R.W., Butler, W.M., Brammer, S.G., Allen, Z.A., Biochemical and functional outcomes following brachytherapy with or without supplemental therapies in men < or =50 years of age with clinically organ-confined prostate cancer (2008) Am J Clin Oncol, 31 (6), pp. 539-544
dc.descriptionAbdel-Wahab, M., Reis, I.M., Hamilton, K., Second primary cancer after radiotherapy for prostate cancer-a SEER analysis of brachytherapy versus external beam radiotherapy (2008) Int J Radiat Oncol Biol Phys, 72 (1), pp. 58-68
dc.languageen
dc.publisherSpringer Verlag
dc.relationWorld Journal of Urology
dc.rightsfechado
dc.sourceScopus
dc.titlePsa-nadir At 1 Year As A Sound Contemporary Prognostic Factor For Low-dose-rate Iodine-125 Seeds Brachytherapy
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución